Search research articles
Contact Us
Filters
Showing results (21-30 of 46) with videos related to
Page
of 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 1999
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
M L Disis, K H Grabstein, P R Sleath, et al.
Annals of the New York Academy of Sciences
|
August 12, 1993
T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl
M A Cheever, W Chen, M L Disis, et al.
Breast Cancer Research and Treatment
|
November 10, 2000
Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer
M L Disis, K L Knutson, K Schiffman, et al.
Critical Reviews in Immunology
|
October 20, 2001
Clinical translation of peptide-based vaccine trials: the HER-2/neu model
M L Disis, K L Knutson, D G McNeel, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
August 1, 1993
Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein
D J Peace, J W Smith, M L Disis, et al.
Cancer Research
|
February 15, 1994
In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein
M L Disis, J W Smith, A E Murphy, et al.
Cancer Research
|
March 1, 1995
Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood
H Bernhard, M L Disis, S Heimfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 1997
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
M L Disis, S M Pupa, J R Gralow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2000
Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization
M L Disis, K Schiffman, T A Gooley, et al.
Endocrine-Related Cancer
|
March 27, 2002
Vaccination against the HER-2/neu oncogenic protein
H Bernhard, L Salazar, K Schiffman, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 46) with videos related to
Sort By:
Page
of 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 1999
Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
M L Disis, K H Grabstein, P R Sleath, et al.
Annals of the New York Academy of Sciences
|
August 12, 1993
T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl
M A Cheever, W Chen, M L Disis, et al.
Breast Cancer Research and Treatment
|
November 10, 2000
Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer
M L Disis, K L Knutson, K Schiffman, et al.
Critical Reviews in Immunology
|
October 20, 2001
Clinical translation of peptide-based vaccine trials: the HER-2/neu model
M L Disis, K L Knutson, D G McNeel, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
|
August 1, 1993
Induction of T cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein
D J Peace, J W Smith, M L Disis, et al.
Cancer Research
|
February 15, 1994
In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein
M L Disis, J W Smith, A E Murphy, et al.
Cancer Research
|
March 1, 1995
Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood
H Bernhard, M L Disis, S Heimfeld, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 1997
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer
M L Disis, S M Pupa, J R Gralow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 25, 2000
Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization
M L Disis, K Schiffman, T A Gooley, et al.
Endocrine-Related Cancer
|
March 27, 2002
Vaccination against the HER-2/neu oncogenic protein
H Bernhard, L Salazar, K Schiffman, et al.
Page
of 5